IT1400609B1 - Associazione di inibitori della xantina ossidasi e metformina e loro uso. - Google Patents

Associazione di inibitori della xantina ossidasi e metformina e loro uso.

Info

Publication number
IT1400609B1
IT1400609B1 ITRM2010A000233A ITRM20100233A IT1400609B1 IT 1400609 B1 IT1400609 B1 IT 1400609B1 IT RM2010A000233 A ITRM2010A000233 A IT RM2010A000233A IT RM20100233 A ITRM20100233 A IT RM20100233A IT 1400609 B1 IT1400609 B1 IT 1400609B1
Authority
IT
Italy
Prior art keywords
xanthin
metformin
association
oxidase
inhibitors
Prior art date
Application number
ITRM2010A000233A
Other languages
English (en)
Inventor
Carlo Alberto Maggi
Sandro Giuliani
Francesco Melani
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Priority to ITRM2010A000233A priority Critical patent/IT1400609B1/it
Priority to TW100116121A priority patent/TW201206431A/zh
Priority to PCT/EP2011/057412 priority patent/WO2011141419A1/en
Priority to ARP110101591A priority patent/AR081024A1/es
Publication of ITRM20100233A1 publication Critical patent/ITRM20100233A1/it
Priority to CR20120617A priority patent/CR20120617A/es
Application granted granted Critical
Publication of IT1400609B1 publication Critical patent/IT1400609B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ITRM2010A000233A 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e metformina e loro uso. IT1400609B1 (it)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ITRM2010A000233A IT1400609B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e metformina e loro uso.
TW100116121A TW201206431A (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and metformin and use thereof
PCT/EP2011/057412 WO2011141419A1 (en) 2010-05-10 2011-05-09 Association of the xanthine oxidase inhibitor febuxostat and metformin and use thereof
ARP110101591A AR081024A1 (es) 2010-05-10 2011-05-09 Asociacion de los inhibidores de la xantina oxidasa y la metformina y su uso
CR20120617A CR20120617A (es) 2010-05-10 2012-12-06 Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2010A000233A IT1400609B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e metformina e loro uso.

Publications (2)

Publication Number Publication Date
ITRM20100233A1 ITRM20100233A1 (it) 2011-11-11
IT1400609B1 true IT1400609B1 (it) 2013-06-14

Family

ID=43519819

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM2010A000233A IT1400609B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e metformina e loro uso.

Country Status (5)

Country Link
AR (1) AR081024A1 (it)
CR (1) CR20120617A (it)
IT (1) IT1400609B1 (it)
TW (1) TW201206431A (it)
WO (1) WO2011141419A1 (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164439A (zh) * 2018-12-06 2021-07-23 安索治疗公司 用于治疗或预防痛风或高尿酸血症的方法
WO2024033705A1 (en) * 2022-08-08 2024-02-15 Xortx Therapeutics, Inc. Xanthine oxidase inhibitor formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645867B2 (en) 1990-11-30 1994-01-27 Teijin Pharma Limited 2-arylthiazole derivative and pharmaceutical composition containing the same
EP1020454B2 (en) 1998-06-19 2013-01-23 Teijin Pharma Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
US20040122067A1 (en) 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
JP5242393B2 (ja) 2005-08-03 2013-07-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド 高血圧症の治療方法
CA2630639A1 (en) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
KR20160031040A (ko) 2006-11-13 2016-03-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
US20100305074A1 (en) * 2007-04-04 2010-12-02 Hight H Thomas Niacin-based pharmaceutical compositions
US20100137289A1 (en) * 2007-04-17 2010-06-03 Johnson Richard J Methods and Compositions for Ameliorating Thiazide Induced Hyperlipidemia

Also Published As

Publication number Publication date
ITRM20100233A1 (it) 2011-11-11
CR20120617A (es) 2013-03-04
TW201206431A (en) 2012-02-16
AR081024A1 (es) 2012-05-30
WO2011141419A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
CY2020025I1 (el) Αναστολεις βητα-λακταμασων
SMT201600135B (it) Nuovi inibitori della s-nitrosoglutatione riduttasi
DK2536722T3 (da) Bicycliske forbindelser og deres anvendelse som dual-c-src-/jak-inhibitorer
SMT201600021B (it) Nuovi composti di chinolina sostituiti come inibitori della s-nitrosoglutatione reduttasi
CY2019026I1 (el) Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης
SMT201600023B (it) Composti piridazinonici e loro uso come inibitori di daao
SMT201600311B (it) Inibitori di cdk
SMT201500271B (it) Inibitori di neprilisina
BR112013025354A2 (pt) combinações de compostos de inibidor de akt e agentes quimioterápicos e métodos de uso
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
DK3590934T3 (da) Pyrazolylquinoxalinkinasehæmmere
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
CO6930362A2 (es) Compuesto heterocíclico y su uso
DK2389352T3 (da) Arginaseinhibitorer og anvendelsesfremgangsmåder
DK2504332T4 (da) Amorf form og krystallinsk form af genz 112638-hemitartrat som inhibitor af glucosylceramidsyntase
DK2513105T3 (da) 2-arylimidazolderivater som pde10a-enzyminhibitorer
CO7020907A2 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
DK2483271T3 (da) Pyrazolindionderivater som NADPH-oxidaseinhibitorer
BR112013013523A2 (pt) centralizador, método, e, uso de um centralizador
BRPI1007494A2 (pt) composto e uso do mesmo
DOP2011000397A (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
DK2513106T3 (da) Heteroaromatiske aryltriazol-derivater som pde10a-enzyminhibitorer
DK3597650T3 (da) Aldosereduktasehæmmere og anvendelser deraf
BR112013006131A2 (pt) inibidores de notum pectinacetilesterase e métodos para sua utilização